Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 14977950 | HLA-DR (HLA-DR) | pertussis | NA | NA | NA | positive+negation | |
| using mutant strains of b. pertussis, we found that reduction in hla-dr surface expression was due in part to the presence of pertussis toxin whereas the inhibition of ifn-gamma induction of hla-dr could not be linked to any of the virulence factors tested. | |||||||
| 14977950 | HLA-DR (HLA-DR) | strains | NA | NA | NA | positive+negation | |
| using mutant strains of b. pertussis, we found that reduction in hla-dr surface expression was due in part to the presence of pertussis toxin whereas the inhibition of ifn-gamma induction of hla-dr could not be linked to any of the virulence factors tested. | |||||||
| 14977950 | HLA-DR (HLA-DR) | pertussis | NA | NA | NA | unclassified | |
| these data demonstrate that b. pertussis utilizes several mechanisms to modulate hla-dr expression. | |||||||
| 14977950 | HLA-DR (HLA-DR) | infection | NA | NA | NA | unclassified | |
| bp338 infection reduced cell surface expression of hla-dr and cd86 but not that of major histocompatibility complex class i proteins. | |||||||
| 14977950 | HLA-DR (HLA-DR) | infection | NA | NA | NA | unclassified | |
| bp338 infection also prevented gamma interferon (ifn-gamma) induction of hla-dr protein synthesis. | |||||||
| 24599530 | MHC (MHC) | pertussis | NA | NA | NA | unclassified | |
| here, we elucidate for the first time the dominant major histocompatibility complex (mhc) class ii-presented b. pertussis cd4(+) t cell epitopes, expressed on human monocyte-derived dendritic cells (mddc) after the processing of whole bacterial cells by use of a platform of immunoproteomics technology. | |||||||
| 24599530 | HLA-DR (HLA-DR) | pertussis | NA | NA | NA | unclassified | |
| pertussis epitopes identified in the context of hla-dr molecules were derived from two envelope proteins, i.e., putative periplasmic protein (ppp) and putative peptidoglycan-associated lipoprotein (pal), and from two cytosolic proteins, i.e., 10-kda chaperonin groes protein (groes) and adenylosuccinate synthetase (ass). | |||||||
| 28008331 | HLA-DR (HLA-DR) | pertussis | NA | prostaglandin | NA | unclassified | |
| omvs were benchmarked against licensed vaccines, including bexsero and whole cell pertussis formulations, with respect to th-polarizing cytokine and prostaglandin e2 production, as well as cell surface activation markers (hla-dr, cd86, and ccr7). | |||||||
| 31507615 | HLA-DR (HLA-DR) | pertussis | NA | NA | NA | unclassified | |
| however, co-culture of b. pertussis-stimulated mo-mph and autologous nk cells resulted in high amounts of ifng secretion and an increased frequency of il-2ra+ and hla-dr+ nk cells, indicating nk cell activation. | |||||||
| 31951773 | HLA-CLASS II (HLA CLASS II) | pertussis | NA | NA | NA | lack_of_evidence | |
| reduced binding affinity to hla class ii was observed for the detolerized variants compared to the wild-type peptides, highlighting the potential of this approach for designing more efficacious pertussis vaccines. | |||||||
Copyright 2024